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Biochemical markers have a central position in the diagnosis and management of patients
in clinical medicine, and also in clinical research and drug development, also for brain
disorders, such as Alzheimer’s disease. The enzyme-linked immunosorbent assay (ELISA)
is frequently used for measurement of low-abundance biomarkers. However, the quality
of ELISA methods varies, which may introduce both systematic and random errors. This
urges the need for more rigorous control of assay performance, regardless of its use
in a research setting, in clinical routine, or drug development. The aim of a method
validation is to present objective evidence that a method fulfills the requirements for its
intended use. Although much has been published on which parameters to investigate
in a method validation, less is available on a detailed level on how to perform the
corresponding experiments. To remedy this, standard operating procedures (SOPs) with
step-by-step instructions for a number of different validation parameters is included in the
present work together with a validation report template, which allow for a well-ordered
presentation of the results. Even though the SOPs were developed with the intended use
for immunochemical methods and to be used for multicenter evaluations, most of them
are generic and can be used for other technologies as well.
Keywords: immunoassays, method validation, precision, limits of quantitation, robustness
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Introduction
Biochemical markers (biomarkers) play a central role in the
decision-making in clinical medicine. Examples include making a
clinical diagnosis, initiating andmonitoring treatment, predicting
prognosis or disease recurrence after treatment. Among brain dis-
orders, the Alzheimer’s disease (AD) field is in the good situation
that a panel of cerebrospinal fluid (CSF) biomarkers is at hand,
including the 42 amino acid variant of β-amyloid (Aβ42), total tau
(T-tau), and phosphorylated tau (P-tau), and have in numerous
studies been shown to have high diagnostic accuracy for AD also
in the early stage of the disease (1). Except for an increasing use
in clinical routine, these biomarkers are also used in clinical trials,
both as diagnostic and as theragnosticmarkers (2). Last, these CSF
biomarkers are applied in clinical studies on disease pathogenesis,
and many research reports present novel biomarker candidates.
The vast majority of such fluid biomarkers are low-abundance
proteins, for which antibody-based immunoassays, often in the
enzyme-linked immunosorbent assay (ELISA) format, is needed
to get enough analytical sensitivity. However, to get reliable and
reproducible results, rigorous control of assay performance is
essential, which also should be presented in a standardized format.
Validation of a method is the confirmation by examination and
the provision of objective evidence that the particular require-
ments for a specific intended use are fulfilled (3). It is important
as it defines whether it will produce reliable results in the context
of its intended use. This last item is sometimes overlooked; the
intended use of amethod needs to be carefully specified before any
time consuming and costly validation experiments are performed.
This notion is generic to any method. However, this paper will
now focus on the validation of methods used to determine analyte
concentrations in biofluids. The intended use for such a method
could be to use the outcome as a diagnosticmarker and in this case
some evidence should be in place showing that there is a disease-
dependent change in the analyte concentration in a biological
sample. Furthermore, the magnitude of the change should have
an impact on the acceptable variability of the method, i.e., if the
change is small the higher is the demand on the precision and on
the analytical sensitivity and specificity.
Much has been published on the topic of method validation
but a consensus protocol on how to perform the task is yet to be
found. This could be partly due to the fact that different analyti-
cal technologies have different requirements on which validation
parameters that need to be addressed or that local initiatives by
national societies in the clinical chemistry field were not discussed
and spread at international level (4). For example, carryover
should be investigated in a chromatography-based method while
it is not applicable in an ELISA. The aim of the present work
was to present straightforward step-by-step standard operating
procedures (SOPs) for the validation of methods in which an
analyte is determined in a biofluid matrix; the SOPs have been
developedwith the intention that they should be possible to follow
without any advanced prior training.
This work is themain deliverable of the sub-task “Development
of assay qualification protocols” in the BIOMARKAPD project
supported by the European Union initiative Joint Programme –
Neurodegenerative Disease Research. The BIOMARKAPD
project aims for standardization of biomarker measurements
for AD and Parkinson’s disease (PD), including pre-analytical
and analytical procedures, assay validation, and development of
reference measurement procedures (RMP) and certified reference
materials (CRM) for harmonization of results across assay formats
and laboratories. The work flow in the present project consisted
of writing draft SOPs for each parameter relevant to validation
of a method for determination of an analyte concentration in a
biofluid. Task members were then asked to review and revise the
SOPs, whereafter they were evaluated in at least three multicenter
studies. End-users commented on the draft SOPs, and, after an
additional round of reviews, final, consensus SOPs were produced
which form the core of the current report. All members of the
task were invited to critically revise the manuscript.
Full vs. Partial Validation
Standard operating procedures for 10 different validation param-
eters are presented. If a method is developed in-house, a full vali-
dation should be performed, meaning that all parameters should
be investigated. As a consensus agreement in the group, it was
decided that a partial validation of a commercial assay should
include all parameters except for robustness, which should have
been covered by the manufacturer during method development.
Even more limited partial validations may be eligible under other
circumstances. For example, if a validated in vitro diagnostic
(IVD) method is transferred to another laboratory to be run
on a different instrument by a different technician it might be
sufficient to revalidate the precision and the limits of quantifica-
tion since these variables are most sensitive to the changes, while
more intrinsic properties for a method, e.g., dilution linearity and
recovery, are not likely to be affected.
It is also advisable to have a dialog with the client/sponsor to
agree to what extent the method should be validated. Unfortu-
nately, the standard ISO 15189 (20), which is designed for clinical
laboratories, does not providemuch rigor by only stating that “The
validations shall be as extensive as are necessary to meet the needs
in the given application or field of application.”
Validation Report
If a laboratory is, or plan to be, accredited to some international
standard there is usually a high demand on documentation. For
example, in order to comply with the standard ISO 15189 “The
laboratory shall record the results obtained and the procedure
used for the validation (20).” To facilitate this and at the same time
allow for a well-ordered presentation of the results a validation
report template can be found in Data Sheet S1 in Supplementary
Material. The template has been adapted from a Swedish hand-
book onmethod validation (5), with the permission of the authors.
Below an outline of the 10 validation parameters is given and a
short definition of each are presented in Table 1. To aid in the
extraction of information from measurement data the Data Sheet
S2 in Supplementary Material can be used.
Robustness
Robustness or ruggedness is the ability of a method to remain
unaffected by small variations in method parameters. If the
instructions from the manufacturer of a commercially available
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TABLE 1 | Short description of the validation parameters for which SOPs are presented.
Parameter Definition Reference
1 Robustness The ability of a method to remain unaffected by small variations in method parameters (6)
2 Precision The closeness of agreement between independent test results obtained under stipulated conditions (7)
3 Trueness The closeness of agreement between the average value obtained from a large series of test results and an
accepted reference value
(7)
4 Uncertainty A parameter associated with the result of a measurement, that characterizes the dispersion of the values
could reasonably be attributed to the measurand
(8)
5 Limits of quantification Highest and lowest concentrations of analyte that have been demonstrated to be measurable with acceptable
levels of precision and accuracy
(6)
6 Dilutional linearity Dilutional linearity is performed to demonstrate that a sample with a spiked concentration above the ULOQ
can be diluted to a concentration within the working range and still give a reliable result
(6)
7 Parallelism Relative accuracy from recovery tests on the biological matrix or diluted matrix against the calibrators in a
substitute matrix
(6)
8 Recovery The recovery of an anlayte in an assay is the detector response obtained from an amount of the analyte added
to and extracted from the biological matrix, compared to the detector response obtained for the true
concentration of the analyte in the solvent
(9)
9 Selectivity The ability of the bioanalytical method to measure and differentiate the analytes in the presence of
components that may be expected to be present
(9)
10 Sample stability The chemical stability of an analyte in a given matrix under specific conditions for given time intervals (9)
assay does not contain any information indicative of a robustness
assessment the manufacturer should be contacted and asked to
provide this information since it is likely that such data is available
given that the method development was sound. In case of an in-
house method, the robustness should be investigated as a part of
themethod development and the results should be reflected in the
assay protocol before other validation parameters are investigated.
The reason for this is that a validation is linked to an assay protocol
and changes in the latter might demand a new validation to be
performed.
Procedure
1. Identify critical parameters in the procedure, e.g., incubation
times and temperatures.
2. Perform the assay with systematic changes in these parameters,
one at the time, using the same set samples at each occasion.
3. If the measured concentrations do not depend on the changes,
adjust the protocol by adding appropriate intervals, e.g.,
30 3min or 23 5°C, to the critical parameters.
4. If the changes systematically alter the measured concentra-
tions, lower the magnitude of the changes until no dependence
is observed. Incorporate the results into the protocol.
Note: if many critical steps are identified the number of exper-
iments can be reduced using dedicated software, e.g., MODDE
(Umetrics) or published methods (10).
Precision
Precision is defined as “The closeness of agreement between inde-
pendent test results obtained under stipulated conditions” (7).
There are three different types of precisions depending on the
stipulated conditions and these are repeatability (r), intermedi-
ate precision (Rw), and reproducibility (R). Repeatability is the
variability observed when as many factors as possible, e.g., labo-
ratory, technician, days, instrument, reagent lot, are held constant
and the time between the measurements is kept to a minimum
as opposed to reproducibility conditions where all factors are
varied and measurements are carried out over several days. For
intermediate precision, all factors except laboratory are allowed
to vary and for clarity the factors changed should be stated in the
validation report. Repeatability is sometimes called within-run or
within-day precision while intermediate precision is also known
as between-run or between day repeatability.
Precision is difficult to quantify and it is therefore the inversely
related imprecision that is commonly reported. Asmeasures of the
imprecision it is usual to report both the SD and coefficient of
variation (%CV) for the different levels of the measurand inves-
tigated with the condition as a subscript, e.g., %CVRw. Analysis of
variance (ANOVA) is used in the estimation of the imprecision
and to facilitate in the calculations an excel file (Data Sheet S3 in
Supplementary Material) has been created using the formulas in
ISO 5725-2 (11).
Procedure
1. Collect samples with known high and low concentrations of
the measurand. Pool samples if necessary.
2. Make 25 aliquots of each sample and store at  80°C pending
analysis.
3. At day 1–5 measure 5 replicates on each sample. Note: the days
need not to be consecutive, only different.
4. Insert data, separate days on different rows, in the excel file
Data Sheet S3 in Supplementary Material that calculates the
mean value, SD, %CV for both the repeatability and interme-
diate precision.
Five samples with different levels have been suggested as a
general rule to cover a wide measuring range (7). However, it can
be argued that if the levels are chosen with care, for example, one
above and one below the decision limit, two samples might be
enough. In addition, it is not always possible to obtain samples
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covering a wide range, e.g., when levels in patients and controls
do not differ much or when these levels are still to be defined. If
large volumes of the samples are available, more aliquots than the
ones needed for the precision measurements can be prepared for
use as internal quality control samples when the method has been
put in service.
Other experimental schemes than the one suggested under
points 2–3 in the procedure are possible, e.g., 12 replicates on
1 day and 3 replicates on 4 different days, or as the Clinical and
Laboratory Standards Institute recommends, 2 separate runs on
20 days (total 40 runs) (12). The latter scheme will allow for more
different factors to be explored, which will give a better estimate
of the variability. At the same time, it is very impractical and
expensive if the method is, e.g., a commercial ELISA kit where
the number of calibrator curves that can be constructed in each
kit-package is usually very limited.
Trueness
Trueness is defined as “The closeness of agreement between the
average value obtained from a large series of test results and
an accepted reference value” (7). Ideally, the reference value is
derived directly from a CRM or from materials that can be traced
to the CRM. The quantity in which the trueness is measured is
called bias (b), which is the systematic difference between the test
result and the accepted reference value.
Procedure
1. Given that there exists a CRM, calculate the bias (bCRM) using
formula (1) where the measured mean value (X) is calculated
from five replicates and xref is the assigned reference value.
2. If there exists an external quality control (QC) program, but
no CRM, the bias (bQC) is calculated as the mean value of
the deviations from the assigned QC values using formula (2).
Note: the biasmight be concentration-dependent and therefore
bQC should preferably be calculated using a longitudinal QC
sample.
Formulas
bCRM = X- Xref (1)
bQC =
Pn
i=1 (Xi   XQCi)
n (2)
where n is the number of measurements, xi is the value measured
in the laboratory, and xQCi is the value from the ith sample in the
QC program.
Once the bias is determined, it can be used to compensate the
measured concentration resulting in a method without systematic
effects (8). If the bias is constant over themeasurement interval the
bias is simply subtracted from themeasured value and if the bias is
proportional to themeasured concentration the correction is done
by multiplication of a factor determined from bias evaluations
at different concentrations. Alternatively, the calibrators can be
assigned new values to compensate for the bias. The total bias is
the sum of two components originating from the method and the
laboratory, respectively. When a CRM is available, manufacturers
are obliged to calibrate their method against materials traceable to
the CRM and then the total bias should in principle be equal to
the laboratory bias.
Uncertainty
The intermediate precision provides information about the dis-
persion characteristics of the results within a laboratory with no
regard to the true value of a measurand in a sample. There-
fore, in the absence of a CRM, the measurements rather deliver
relative concentrations as opposed to absolute ones that can be
achieved if the calibrators were traceable to a CRM. However, if
different methods can be used for quantifying the same analyte
and if a universal cutoff value is warranted there is a need for a
CRM that can be used by the kit manufacturers to calibrate their
methods against, in order to minimize the bias. This will also
enable calculating absolute concentrations but the uncertainty
in the results must then include not only the uncertainty from
the method but also the uncertainty of the assigned value for
the CRM.
Procedure
1. Given that there exists a CRM, calculate the combined uncer-
tainty (uc) from the standard uncertainty of the precision
(uprecision) and the CRM (uCRM) using formula (3). Note: both
uprecision and uCRM have to be SDs. Note: this way of calculating
the uc assumes that the bias has been adjusted for as outlined in
the trueness section above. Note: the results from the precision
measurements can be used as an estimate of the uncertainty,
e.g., uprecision= sRW.
2. Calculate the expanded uncertainty (U) using formula (4).
Note: the coverage factor (k) is set to 2 for a confidence interval
of approximately 95%. Note: the coverage factor for a given
confidence interval is dependent on the degrees of freedom.
Details on this and coverage factors for other confidence inter-
vals can be found elsewhere (8).
Formulas
uc =
q
(uprecision)2 + (uCRM)2 (3)
U = k  uc (4)
Limits of Quantification
The working range for amethod is defined by the lower and upper
limits of quantification (LLOQ and ULOQ, respectively). At least
for the LLOQ, there is more than one definition and these can
be classified as either determined based on the signals from the
instrument or the calculated concentrations from samples. For the
former, a number of blank samples are analyzed and the average
and SD of the signal are calculated (13).
Procedure
1. Run 16 blank samples (immunodepleted matrix or sample
diluent)
2. Calculate the mean and SD of the signal.
3. Determine the concentration based on a signal of 10 SDs above
the mean of the blank. Note: this procedure gives only the
LLOQ but not the ULOQ.
To determine the concentration based on a signal the inverse
of the calibration function must be used. The two most common
models used in immunochemical calibrations are the four and five
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parametric logistic models. The four parametric function and its
inverse are:
Signal = A  D
1+
 Concentration
C
B + D, Concentration
= C

A  D
Signal  D   1
 1
B
(5)
For the five-parameter logistic model the corresponding func-
tions are:
Signal = A  D
1+
 Concentration
C
BE + D, Concentration
= C
 
A  D
Signal  D   1
 1
E
  1
! 1
B
(6)
The parametersA–E should be available from the software used
for data acquisition and analysis.
Based on the concentrations the LLOQ and ULOQ can be
defined as the endpoints of an interval in which the %CV is
under a specific level with the option of a higher %CV at the
endpoints (9, 14).
Procedure
1. Analyze, in duplicates, samples with very low and very high
concentrations of the measurand.
2. Calculate the average concentration and%CVs for the samples.
3. Make a scatter plot of the %CV as a function of concentration
for all samples.
4. Determine the LLOQ by identifying the lowest mean level
above which the %CV< 20% for the greater majority of the
samples.
5. Determine the ULOQ by identifying the highest mean level
below which the %CV< 20% for the greater majority of the
samples.
Dilution Linearity
Dilution linearity is performed to demonstrate that a sample with
a spiked concentration above the ULOQ can be diluted to a con-
centration within the working range and still give a reliable result.
In other words, it determines to which extent the dose–response
of the analyte is linear in a particular diluent within the range of
the standard curve. Thereby dilution of samples should not affect
the accuracy and precision. At the same time, the presence of a
hook effect, i.e., suppression of signal at concentrations above the
ULOQ, is investigated.
Procedure
1. Spike three samples (undiluted) with calibrator stock solution,
as high as possible. Note: if possible, spike (undiluted) samples
with 100- to 1000-fold the concentration at ULOQ using the
calibrator stock solution. Biological samples can also be diluted
less than the prescribed concentration, if an assay allows to.
2. Make serial dilutions of the spiked samples, using sample dilu-
ent in small vials until the theoretical concentration is below
LLOQ. Note: the dilution should be performed using vials and
not directly in the wells of the ELISA plate.
3. Analyze the serial dilutions in duplicates and compensate for
the dilution factor.
4. Calculate for each sample the mean concentration for the
dilutions that fall into the range of LLOQ and ULOQ. More-
over, calculate for each sample the %Recovery for the cal-
culated concentration at each dilution. Note: the calculated
concentration for a dilution that fall into the range of LLOQ
and ULOQ should be within the acceptance criteria for the
precision defined in the “SOP for fit-for-purpose” as should
the calculated SD. Also, plot the signal against the dilu-
tion factor to investigate if the signal is suppressed at much
higher concentrations than the ULOQ of the measurand
(“hook effect”).
Dilution linearity should not be confused with linearity of
quantitative measurement procedures as defined by CLSI (15),
which concerns the linearity of the calibration curve.
Parallelism
Conceptually parallelism and dilution linearity are similar. The
major difference is that in the dilution linearity experiments the
samples are spiked with the analyte to such a high concentra-
tion that after dilution the effect of the sample matrix is likely
to be negligible. For parallelism, on the other hand, no spiking
is allowed but only samples with high endogenous concentra-
tions of the analyte must be used. However, the concentrations
must be lower than the ULOQ. The goal of investigating the
parallelism is to ascertain that the binding characteristic of the
endogenous analyte to the antibodies is the same as for the
calibrator.
Procedure
1. Identify four samples with high, but belowULOQ, endogenous
concentration of the measurand.
2. Make at least three, two-fold serial dilutions using sample dilu-
ent in reaction vials until the calculated concentration is below
LLOQ. Note: the dilution factor should be adjusted to obtain
concentrations that are evenly spread over the standard curve.
For example, dilution factor 10 if a standard curve includes
values between 0.1 and 200 pg/ml.
3. Analyze the neat samples and the serial dilutions in duplicates,
in the same run, and compensate for the dilution factor.
4. For each sample, calculate the %CV using results from neat
sample and the dilutions.
There are different views on what the acceptance criteria for
the %CV should be for showing the presence of parallelism. It has
been suggested that %CV 30% for the samples in the dilution
series is enough (14, 16) while others advocate a lower level
of below 20% (17) or within the range 75–125% compared to
the neat sample (18). None of these suggestions, however, relate
the acceptance criteria to the precision of the method under
investigation.
Recovery
The recovery of an analyte in an assay is the detector response
obtained from an amount of the analyte added to and extracted
from the biological matrix, compared to the detector response
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obtained for the true concentration of the analyte in solvent
(9). A spike recovery test is conducted to investigate if the
concentration–response relationship is similar in the calibration
curve and the samples. A bad outcome of the test suggests that
there are differences between the sample matrix and calibra-
tor diluent that affects the response in signal. Data obtained
from this study could help to find a diluent mimicking the bio-
logical sample in which the calibrator and the native protein
give the comparable detector signals all along the measuring
range.
Procedure
1. Collect five samples were the concentrations of the measurand
have previously been determined and divide each sample into
4 aliquots.
2. Spike three of the aliquots, using calibrator stock solution,
to expected concentrations that are evenly distributed over
the linear range of the standard curve (low, medium, high).
Note: all additions should be in the same volume, preferable
<10% of the sample volume. The same volume of measurand-
free calibrator diluent must also be added to the neat sam-
ple (fourth aliquot) to compensate for the dilution. Note:
the theoretical concentration in the spiked samples should
be lower than the ULOQ. Different spiking concentrations
should be used to investigate possible dependency on the
amount of added substance. The low spike should be slightly
higher than the lowest reliable detectable concentration. Note:
alternatively, samples can be spiked after dilution if there
is limited availability of the calibrator and high working
dilutions.
3. Analyze both the neat and spiked samples in the same run.
Dilute each sample as advised for each assay to be used,
4. Calculate the recovery using formula (7). Note: acceptance
range for the recovery is usually 80–120%.
% Recovery =
Measured concentrationspiked sample
 Measuered concentrationneat sample
Theoretical concentrationspiked
 100
(7)
Selectivity
Selectivity can be defined as “the ability of the bioanalytical
method to measure and differentiate the analytes in the presence
of components that may be expected to be present” (9). The
terms “selectivity” and “specificity” are often used interchangeably
while their significances are different. Selectivity is something
that can be graded while specificity is an absolute character-
istic. Specificity can be considered as the ultimate selectivity.
For this reasons, selectivity should be preferred and is the rec-
ommended terminology. Of the different validation parameters
the selectivity is in principle the only one for which a certain
amount of knowledge about the analyte and related substances
is demanded. For example, if the analyte is a peptide of a spe-
cific length do slightly longer or shorter peptides also give rise
to a signal in the assay? Do metabolites of the analyte or post
translational modifications of a protein analyte interfere with the
assay?
Procedure
1. Identify substances that are physiochemically similar to the one
that the assay is developed for.
2. Investigate to what degree the measurements are interfered
by spiking samples with substances identified in step 1. Note:
if information is available regarding the endogenous concen-
tration of an investigated substance the spiking concentration
should be at least two times the reference limit. Otherwise a
titration is recommended.
3. For antibody-based methods, an epitope mapping should be
performed.
Sample stability
Sample handling prior to analysis has the potential to dra-
matically influence the results of a measurement. For this rea-
son, it is important to investigate if different storage conditions
contribute to systematic errors in order to provide the clini-
cians with adequate sample collection and transport instructions.
The information gathered will also be useful once the sam-
ple reaches the laboratory, i.e., how it should be stored until
analysis or pending a possible need for a re-run. Examples of
factors that potentially affect the results of an analysis, but are
not included in the following procedure includes, sample tube,
type of plasma anticoagulant, gradient effects (concerns CSF
samples), centrifugation conditions, extended mixing, and diur-
nal variations. If data are not available on how these factors
influence the measurement the sample instructions should be
written in a way to prevent variations potentially induced by
these.
Procedure
1. Repeat the following steps for three independent samples,
preferably with different concentrations of the measurand
(low, medium, high).
2. Divide the sample into nineteen aliquots with equal sample
volume.
Note: it is important that every aliquot contains the same
sample volume and to use the same kind of reaction vials,
since unequal sample volumes may affect the concentration
of the measurand due to adsorption.
3. Place aliquots #1–6 at 80°C.
4. Thaw aliquots #2–6 and store again at 80°C.
Note: thaw for 2 h at room temperature and next store the
sample at least 12 h at 80°C for each freeze/thaw cycle.
5. Thaw aliquots #3–6 and store again at 80°C.
6. Thaw aliquots #4–6 and store again at 80°C.
7. Thaw aliquot #5–6 and store again at 80°C.
8. Thaw aliquot #5–6 and store again at 80°C.
9. Thaw aliquot #6 and store again at 80°C.
10. Thaw aliquot #6 and store again at 80°C.
11. At time point 0, store aliquots #7–12 at room temperature and
another six aliquots #13–18 at 4°C.
12. At time points t= 1 h, t= 2 h, t= 4 h, t= 24 h, t= 72 h,
t= 168 h, transfer one sample stored at each temperature, RT
and 4°C, to 80°C.
13. Store aliquot #19 at  20°C during 1month before transfer to
 80°C.
Frontiers in Neurology | www.frontiersin.org August 2015 | Volume 6 | Article 1796
Andreasson et al. A practical guide to immunoassay method validation
14. Thaw all aliquots for a given sample simultaneously and
analyze them in duplicates in the same run.
15. Insert raw data of aliquots #1–19 (replicates of observed
concentrations) in the Excel file Data Sheet S4 in Supple-
mentary Material. The file calculates the mean value, SD,
and coefficient of variation (%CV) for both the observed
concentration and normalized concentration. Note: the SD
for the storage conditions and the freeze/thaw aliquots should
be within the acceptance criteria for the precision defined in
the fit-for-purpose.
The above conditions tested should only serve as an example
and the can be modified to better suit the environment and differ-
ent routine handling of samples at the individual laboratories.
Internal Quality Control Program
The experiments in a validation are usually performed within
a month time and therefore the results represent a kind of
snapshot of the performance characteristics of the method. To
ascertain that the quality does not degrade over time an inter-
nal quality control program should be initiated before the assay
is taken into service. The results from quality control sam-
ples should be used to determine if a run is accepted and
the objective multi rules presented by Westgard should be
used (19).
Summary
In the present study, we present SOPs for validation of assays
for biochemical markers together with a template for validation
reports. Although this study is part of a project on biomarkers
for AD and PD, the SOPs and validation report is generalizable
to biomarker assays in any field of clinical medicine. The main
focus for the presented SOPs has been on validation parameters
relevant to immunochemical methods such as ELISA and related
techniques for determination of the concentration of an analyte
in a biofluid. Still, many of the parameters are generic and the
SOPs could be used outside the realm of immunochemistry. It
should also be stressed that the procedures presented here are
practical suggestions on how to collect the information needed
to demonstrate that the requirements for a method are fulfilled.
As such, they could be used also by persons with limited expe-
rience in the field of method validation. We believe that vali-
dation of biomarker assays before introduction in clinical rou-
tine or implementation in clinical trials is essential to get reli-
able and interpretable results. Information on assay validation
is also important in research reports on novel biomarker candi-
dates.
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